SJS Investment Consulting’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$68.9K Sell
666
-37
-5% -$3.3K 0.01% 319
2026
Q1
$50.5K Sell
703
-11
-2% -$847 0.01% 384
2025
Q4
$56.6K Buy
714
+26
+4% +$2.05K 0.01% 312
2025
Q3
$51.8K Buy
688
+646
+1,538% +$44.3K 0.01% 271
2025
Q2
$2.87K Sell
42
-44
-51% -$2.88K ﹤0.01% 476
2025
Q1
$5.8K Buy
86
+50
+139% +$2.99K ﹤0.01% 430
2024
Q4
$1.6K Sell
36
-254
-88% -$14.2K ﹤0.01% 817
2024
Q3
$18.2K Buy
290
+218
+303% +$12.7K ﹤0.01% 292
2024
Q2
$4.25K Sell
72
-14
-16% -$876 ﹤0.01% 473
2024
Q1
$6.86K Sell
86
-133
-61% -$10.2K ﹤0.01% 408
2023
Q4
$17.3K Buy
219
+112
+105% +$7.97K ﹤0.01% 247
2023
Q3
$7.47K Buy
107
+13
+14% +$921 ﹤0.01% 315
2023
Q2
$6.5K Sell
94
-46
-33% -$3.27K ﹤0.01% 318
2023
Q1
$10.4K Sell
140
-122
-47% -$10.2K ﹤0.01% 288
2022
Q4
$24.4K Buy
262
+29
+12% +$2.8K 0.01% 215
2022
Q3
$22K Buy
+233
New +$23.1K 0.01% 225
2022
Q1
$27K Buy
265
+36
+16% +$3.78K 0.01% 258
2021
Q4
$24K Buy
+229
New +$21.2K 0.01% 247

Other funds holding CVS

SJS Investment Consulting's CVS Position: Q2 2026 in Review

SJS Investment Consulting reduced its CVS Health (CVS) stake by 5.3% in Q2 2026, selling an estimated $3.3K and leaving 666 shares worth $68.9K. The position accounts for 0.01% of the portfolio, ranked #319.

SJS Investment Consulting first reported a position in CVS in Q4 2021 and has held it in 18 quarters since. 857 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • SJS Investment Consulting held 666 shares of CVS Health worth $68.9K as of Q2 2026.
  • SJS Investment Consulting sold 37 CVS Health shares in Q2 2026, an estimated $3.3K.
  • CVS Health made up 0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #319 holding.
  • SJS Investment Consulting first reported a position in CVS Health in Q4 2021 and has held it in 18 quarters since.
  • 857 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.